

World Journal of *Hepatology*

World J Hepatol 2017 December 28; 9(36): 1296-1388



**MINIREVIEWS**

- 1296** Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus
Kamiyama T, Kakisaka T, Orimo T, Wakayama K
- 1305** Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection
Irshad M, Gupta P, Irshad K

ORIGINAL ARTICLE**Retrospective Cohort Study**

- 1315** Recent trends in liver transplantation for alcoholic liver disease in the United States
Kling CE, Perkins JD, Carithers RL, Donovan DM, Sibulesky L
- 1322** Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma
Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliente F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M
- 1332** Hospital contacts with alcohol problems prior to liver cirrhosis or pancreatitis diagnosis
Askgaard G, Neermark S, Leon DA, Kjær MS, Tolstrup JS
- 1340** Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1
Ozono Y, Nagata K, Hasuike S, Iwakiri H, Nakamura K, Tsuchimochi M, Yamada Y, Takaishi Y, Sueta M, Miike T, Tahara Y, Yamamoto S, Shide K, Hidaka T, Kubuki Y, Kusumoto K, Ochiai T, Kato J, Komada N, Hirono S, Kuroki K, Shigehira M, Shimoda K

Retrospective Study

- 1346** Women receive more inpatient resections and ablations for hepatocellular carcinoma than men
Sobotka L, Hinton A, Conteh L
- 1352** Impact of sustained virologic response on chronic kidney disease progression in hepatitis C
Aby ES, Dong TS, Kawamoto J, Pisegna JR, Benhammou JN

CASE REPORT

- 1361 *De-novo* hepatocellular carcinoma after pediatric living donor liver transplantation
Torres-Landa S, Munoz-Abraham AS, Fortune BE, Gurung A, Pollak J, Emre SH, Rodriguez-Davalos MI, Schilsky ML
- 1367 Autoimmune hepatitis in the setting of human immunodeficiency virus infection: A case series
Ofori E, Ramai D, Ona MA, Reddy M
- 1372 Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma
Vouche M, Degrez T, Bouazza F, Delatte P, Gomez Galdon M, Hendlitz A, Flamen P, Donckier V
- 1378 Primary biliary cholangitis metachronously complicated with combined hepatocellular carcinoma-cholangiocellular carcinoma and hepatocellular carcinoma
Ide R, Oshita A, Nishisaka T, Nakahara H, Aimitsu S, Itamoto T
- 1385 Eosinophilic cholangitis treatment with budesonide
De Roza MA, Lim CH

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Toshiya Kamiyama, MD, PhD, Assistant Professor, Surgeon, Surgical Oncologist, Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan

AIM AND SCOPE

World Journal of Hepatology (*World J Hepatol*, *WJH*, online ISSN 1948-5182, DOI: 10.4254), is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJH covers topics concerning liver biology/pathology, cirrhosis and its complications, liver fibrosis, liver failure, portal hypertension, hepatitis B and C and inflammatory disorders, steatohepatitis and metabolic liver disease, hepatocellular carcinoma, biliary tract disease, autoimmune disease, cholestatic and biliary disease, transplantation, genetics, epidemiology, microbiology, molecular and cell biology, nutrition, geriatric and pediatric hepatology, diagnosis and screening, endoscopy, imaging, and advanced technology. Priority publication will be given to articles concerning diagnosis and treatment of hepatology diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJH*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING

World Journal of Hepatology is now indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, and Scopus.

FLYLEAF

I-IV Editorial Board

EDITORS FOR
THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Jin-Li Yan*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Li-Jun Cui*
Proofing Editorial Office Director: *Xin-Xia Song*

NAME OF JOURNAL
World Journal of Hepatology

ISSN
ISSN 1948-5182 (online)

LAUNCH DATE
October 31, 2009

FREQUENCY
36 Issues/Year (8th, 18th, and 28th of each month)

EDITORS-IN-CHIEF
Clara Balsano, PhD, Professor, Department of Biomedicine, Institute of Molecular Biology and Pathology, Rome 00161, Italy

Wan-Long Chuang, MD, PhD, Doctor, Professor, Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com>

www.wjgnet.com/1948-5182/editorialboard.htm

EDITORIAL OFFICE
Xiu-Xia Song, Director
World Journal of Hepatology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
December 28, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
<http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Retrospective Cohort Study

Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma

Francesca Romana Ponziani, Irene Spinelli, Emanuele Rinninella, Lucia Cerrito, Antonio Saviano, Alfonso Wolfango Avolio, Michele Basso, Luca Miele, Laura Riccardi, Maria Assunta Zocco, Brigida Eleonora Annicchiarico, Matteo Garcovich, Marco Biolato, Giuseppe Marrone, Anna Maria De Gaetano, Roberto Iezzi, Felice Giuliani, Fabio Maria Vecchio, Salvatore Agnes, Giovanni Addolorato, Massimo Siciliano, Gian Lodovico Rapaccini, Antonio Grieco, Antonio Gasbarrini, Maurizio Pompili

Francesca Romana Ponziani, Irene Spinelli, Emanuele Rinninella, Lucia Cerrito, Antonio Saviano, Luca Miele, Laura Riccardi, Maria Assunta Zocco, Brigida Eleonora Annicchiarico, Matteo Garcovich, Marco Biolato, Giuseppe Marrone, Giovanni Addolorato, Massimo Siciliano, Gian Lodovico Rapaccini, Antonio Grieco, Antonio Gasbarrini, Maurizio Pompili, Department of Internal Medicine, Gastroenterology and Hepatology, Agostino Gemelli Hospital, Rome 00168, Italy

Alfonso Wolfango Avolio, Salvatore Agnes, Department of Liver Transplant Surgery, Agostino Gemelli Hospital, Rome 00168, Italy

Michele Basso, Department of Oncology, Gastroenterology and Hepatology, Agostino Gemelli Hospital, Rome 00168, Italy

Anna Maria De Gaetano, Roberto Iezzi, Department of Bioimaging and Radiological Sciences, Agostino Gemelli Hospital, Rome 00168, Italy

Felice Giuliani, Department of Hepatobiliary Surgery, Agostino Gemelli Hospital, Rome 00168, Italy

Fabio Maria Vecchio, Department of Pathology, Agostino Gemelli Hospital, Rome 00168, Italy

ORCID number: Francesca Romana Ponziani (0000-0002-5924-6238); Irene Spinelli (0000-0002-9399-4846); Emanuele Rinninella (0000-0002-9165-2367); Lucia Cerrito (0000-0001-6837-7582); Antonio Saviano (0000-0001-7585-472X); Alfonso Wolfango Avolio (0000-0003-2491-7625); Michele Basso (0000-0002-9167-7724); Luca Miele (0000-0003-3464-0068); Laura Riccardi (0000-0001-6249-0314); Maria Assunta Zocco (0000-0002-0814-9542); Brigida Eleonora Annicchiarico (0000-0002-9230-5607); Matteo Garcovich (0000-0002-5805-7953); Marco Biolato (0000-0002-5172-8208); Giuseppe

Marrone (0000-0002-9475-3948); Anna Maria De Gaetano (0000-0002-7493-9462); Roberto Iezzi (0000-0002-2791-481X); Felice Giuliani (0000-0001-9517-8220); Fabio Maria Vecchio (0000-0002-9197-2264); Salvatore Agnes (0000-0002-3341-4221); Giovanni Addolorato (0000-0002-1522-9946); Massimo Siciliano (0000-0001-7167-7893); Gian Lodovico Rapaccini (0000-0002-6467-857X); Antonio Grieco (0000-0002-0544-8993); Antonio Gasbarrini (0000-0002-6230-1779); Maurizio Pompili (0000-0001-6699-7980).

Author contributions: Ponziani FR designed and performed the research, collected data, wrote the paper, performed statistical analysis, revised and approved the final version of the paper; Spinelli I collected data, wrote the paper, revised and approved the final version of the paper; Pompili M, Avolio AW, Siciliano M, Basso M and Miele L contributed to statistical analysis, wrote the paper, revised and approved the final version of the paper; Rinninella E, Cerrito L, Saviano A, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giuliani F, Vecchio FM, Agnes S, Addolorato G, Rapaccini GL, Grieco A and Gasbarrini A contributed to this paper.

Institutional review board statement: This is a retrospective study based on the revision of anonymous clinical data; no additional interventional procedures or drug was performed/administered to the study population. Therefore, no institutional review board approval was required.

Informed consent statement: This is a retrospective study based on the revision of anonymous clinical data; no additional interventional procedures or drug was performed/administered to the study population. Therefore, no informed consent was obtained by the patients.

Conflict-of-interest statement: The authors declare no conflict

of interest.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Dr. Francesca Romana Ponziani, MD, Department of Internal Medicine, Gastroenterology and Hepatology, Agostino Gemelli Hospital, Largo Agostino Gemelli 8, Rome 00168, Italy. francesca.ponziani@yahoo.it
Telephone: +39-34-71227242

Received: August 27, 2017

Peer-review started: August 30, 2017

First decision: September 21, 2017

Revised: October 12, 2017

Accepted: November 11, 2017

Article in press: November 12, 2017

Published online: December 28, 2017

Abstract

AIM

To characterize the survival of cirrhotic patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) and to ascertain the factors predicting the achievement of disease control (DC).

METHODS

The cirrhotic patients with BCLC stage C HCC evaluated by the Hepatocatt multidisciplinary group were subjected to the investigation. Demographic, clinical and tumor features, along with the best tumor response and overall survival were recorded.

RESULTS

One hundred and ten BCLC stage C patients were included in the analysis; the median overall survival was 13.4 mo (95%CI: 10.6-17.0). Only alphafetoprotein (AFP) serum level > 200 ng/mL and DC could independently predict survival but in a time dependent manner, the former was significantly associated with increased risk of mortality within the first 6 mo of follow-up (HR = 5.073, 95%CI: 2.159-11.916, $P = 0.0002$), whereas the latter showed a protective effect against death after one year (HR = 0.110, 95%CI: 0.038-0.314, $P < 0.0001$). Only patients showing microvascular invasion and/or extrahepatic spread recorded lower chances of achieving DC (OR = 0.263, 95%CI: 0.111-0.622, $P = 0.002$).

CONCLUSION

The BCLC stage C HCC includes a wide heterogeneous

group of cirrhotic patients suitable for potentially curative treatments. The reverse and time dependent effect of AFP serum level and DC on patients' survival confers them as useful predictive tools for treatment management and clinical decisions.

Key words: Hepatocellular carcinoma; Cirrhosis; Barcelona Clinic Liver Cancer stage C; Alphafetoprotein; Disease control; Performance status; Survival

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Refining the prognosis of Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) is crucial to select patients that can get benefit from and be suitable for locoregional or surgical treatments. This study confirms that high alphafetoprotein serum level and DC are the best predictors of mortality for BCLC C patients, highlighting that the effect of these two variables is reverse and dynamic, in a time dependent manner. Outstandingly, performance status has not been found to be a strong predictor of mortality. According to our results, curative treatments should not be "a priori" excluded in a subset of BCLC stage C patients with favorable prognostic factors.

Ponziani FR, Spinelli I, Rinninella E, Cerrito L, Saviano A, Avolio AW, Basso M, Miele L, Riccardi L, Zocco MA, Annicchiarico BE, Garcovich M, Biolato M, Marrone G, De Gaetano AM, Iezzi R, Giulianti F, Vecchio FM, Agnes S, Addolorato G, Siciliano M, Rapaccini GL, Grieco A, Gasbarrini A, Pompili M. Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. *World J Hepatol* 2017; 9(36): 1322-1331 Available from: URL: <http://www.wjgnet.com/1948-5182/full/v9/i36/1322.htm> DOI: <http://dx.doi.org/10.4254/wjh.v9.i36.1322>

INTRODUCTION

Hepatocellular carcinoma (HCC) has been recognized as a major health problem, as it ranks third among the leading causes of death due to cancer and is the sixth most common tumor with a worldwide occurrence^[1].

While there are several options available for the treatment of HCC, their choice most likely depends on tumor stage, impairment of normal liver function, patient's performance status (PS) and comorbidities. The most widely accepted staging system for HCC is the Barcelona Clinic Liver Cancer (BCLC), which was based on the patients clinical features along with tumor-related variables and therefore categorized five different stages with progressively worsening prognosis and different treatment options^[1,2].

The patients with an advanced HCC belong to the BCLC stage C, which includes tumors with macrovascular invasion, and/or extrahepatic spread

and/or mild cancer-related symptoms, PS 1-2 (Eastern Cooperative Oncology Group), and mild to moderate liver function impairment (Child-Pugh stage A-B). The only therapeutic option recommended for BCLC stage C HCC is the drug sorafenib, a multikinase inhibitor that has been reported to extend the overall survival of patients up to nearly 3 mo^[3].

Given the higher number of heterogeneous and complex cases encountered in the field-practice, the BCLC classification is often not exhaustive, and the increasing number of new therapeutic options and their combinations makes difficult to strictly adhere to BCLC suggestions. This has been largely demonstrated in other categories of patients such as those belonging to the BCLC stage B group, who had not been subjected to transarterial chemoembolization (TACE), the treatment recommended by the BCLC algorithm, in more than one third of cases^[4-6].

The BCLC stage C HCC encompasses a wide spectrum of tumors and patients' with different characteristics that may get benefit from and be suitable for locoregional or surgical treatments^[7-9]. Nonetheless, in this stage too, the universal administration of sorafenib to the patients following the BCLC algorithm may sometimes be arguable and other therapeutic options could be explored according to patient's individual conditions.

The current study is principally aimed at characterizing the prognosis of cirrhotic patients with BCLC stage C HCC as assessed by a multidisciplinary team in an Italian tertiary care center. In addition to this, the other objective is the identification of the factors predicting the achievement of disease control (DC).

MATERIALS AND METHODS

The present study was performed at the Agostino Gemelli University Hospital, Rome, Italy. The prospective database of the Hepatocatt multidisciplinary group, containing clinical, tumor and outcome data of all liver cancer subjects evaluated in the seven years at our Institute was reviewed, and the cohort of cirrhotic patients with BCLC stage C HCC were selected as the prime object of the investigation.

The following criteria were adopted for the selection of patients: PS grade ≤ 2 ; Child-Pugh class A or B; tumor macrovascular invasion (mainly portal vein and/or hepatic veins and/or inferior vena cava); and/or extrahepatic spread. The HCC was diagnosed by multiphasic contrast-enhanced computed tomography (CT), gadolinium-enhanced magnetic resonance imaging (MRI) and/or by ultrasound-guided biopsy, as per the guidelines of European Association for the Study of the Liver and the American Association for the Study of Liver Diseases^[1,2]. Based on the liver function and patients' characteristics, the modalities of HCC treatment were decided by the Hepatocatt multidisciplinary board, comprising of hepatologists, hepatobiliary and transplant surgeons, oncologists, radiologists, and pathologists. The imaging criteria

(CT and/or MRI) for assessing the tumor response established by mRECIST were followed^[10]. For individual patient, the treatment outcome was documented; DC was achieved in those patients who acquired a stable disease (SD), partial response (PR) or complete response (CR) as the best treatment outcome.

The patients' survival was the measure of success as primary outcome. The follow-up time was defined as the number of months from the entry in the BCLC stage C till their death or last visit. The factors that could predict the achievement of DC were also investigated as secondary endpoint.

Statistical analysis

Statistical analysis was performed using non-parametric tests due to the non normal distribution of data. The continuous variables were expressed as median and range, while the categorical variables as frequencies and percentages.

Pre-treatment variables [Child-Pugh score, PS, number and maximum size of HCC lesions, presence of macrovascular invasion or extrahepatic spread, alphafetoprotein (AFP) serum level, NIACE score value^[11], and diabetes] and post-treatment variables (the number of treatments received after entry in the BCLC stage C and the achievement of DC) were considered as prognostic factors of patients' survival. The univariate analysis of survival estimates was performed using the Kaplan-Meier curve and the *log-rank* test was applied to check the differences between the groups. The variables with a $P < 0.100$ were included in the Cox proportional hazard regression model for the multivariate survival analysis, adjusting for gender and age.

The assumption of proportionality was confirmed by plotting the scaled Schoenfeld residuals over the time [log hazard ratio (beta) over time] and by performing a non-proportionality test (Pearson correlation test) for the overall model and for each covariate of the model. Interaction terms were subsequently introduced in the analysis for that factors that varied significantly over time. Fisher's exact test and binomial logistic regression were performed to identify the predictors of DC among pre- and post-treatment variables.

Statistical analysis was carried out using the R statistics program version 3.1.2. All statistical tests were two-sided and differences were considered significant at $P < 0.05$.

RESULTS

A total of 1030 records of liver cancer patients evaluated between May 2008 and May 2015 were reviewed, of which, 146 non-HCC liver tumors and 774 HCC in BCLC stage other than C (0, A, B or D) were disqualified from the study. Therefore, finally, 110 patients classified as BCLC stage C were included in the investigation. Clinical data and tumor characteristics of the study population are given in Table 1.

Table 1 Clinical and tumor characteristics of patients included in the study

Variable	Overall (110)
Age (yr)	67.5 (41-80)
Gender	
Male	91 (82.7)
Female	19 (17.3)
Etiology of liver disease	
Viral (HBV/HCV/HDV and HCV)	70 (63.6)
Alcohol	17 (15.5)
NASH/NAFLD	14 (12.7)
Viral and alcohol	9 (8.2)
PS	
0	33 (30)
1	64 (58.2)
2	13 (11.8)
Diabetes	
No	87 (79.1)
Yes	23 (20.9)
Child-Pugh score	
A	82 (74.5)
B	28 (25.5)
N nodules	
Single	35 (31.8)
2-3	20 (18.2)
> 3 or infiltrating	55 (50)
Maximum size	
≤ 5 cm	56 (50.9)
> 5 cm	54 (49.1)
Macrovascular invasion	
No	60 (54.5)
Yes	50 (45.5)
Extrahepatic spread	
No	91 (82.7)
Yes	19 (17.3)
Macrovascular invasion and/or extrahepatic spread	
No	49 (44.5)
Yes	61 (55.5)
NIACE	
≤ 3	84 (76.4)
> 3	26 (23.6)
AFP	
≤ 200 ng/mL	74 (67.3)
> 200 ng/mL	36 (32.7)
Treatment before BCLC C diagnosis	
No	53 (48.2)
Yes	57 (51.8)
Type of treatment before BCLC C diagnosis (one or more per patient)	
TACE	35
Surgical resection	20
RFA	18
Sorafenib	13
PEI	11
TACE + RFA	8
TARE	4
DSM-TACE	1
Number of treatments after BCLC C diagnosis	
None	22 (20)
Single	32 (29.1)
Multiple	56 (50.9)
Type of treatment after BCLC C diagnosis (one or more per patient)	
Sorafenib	53
TACE	25
TARE	18
Second line systemic agent	15
PEI	12
DSM-TACE	5

LT	3
RFA	1
Best tumor response	
CR	10 (9.1)
PR	21 (19.1)
SD	12 (10.9)
PD	67 (60.9)
DC	
No	67 (60.9)
Yes	43 (39.1)

Continuous variables are reported as median value and range, categorical variables as frequencies and percentage. HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Nonalcoholic Steatohepatitis; NAFLD: Nonalcoholic fatty liver disease; PS: Performance status; AFP: Alphafetoprotein; DC: Disease control; TACE: Transarterial chemoembolization; TARE: Transarterial radioembolization; DSM-TACE: Degradable starch microspheres transarterial chemoembolization; PEI: Percutaneous ethanol injection; RFA: Radiofrequency ablation; LT: Liver transplant; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; DC: Disease control.

Primary endpoint: Patients' survival

Out of 110 BCLC stage C patients included in the investigation, only 32 received a single treatment and 56 more than once, whereas 22 of them received only best supportive care due to the inadequate liver function. Sorafenib was the most common choice of treatment, followed by TACE, TARE, and second-line systemic agents in patients who were either intolerant to sorafenib or sorafenib failed for them (Table 1). In selected cases, PEI or RFA in combination with other treatments and DSM-TACE were also performed; three PS 1 patients without macrovascular invasion or extrahepatic spread and with tumors complying the Milan criteria after effective downstaging (when needed) underwent liver transplant (LT). The best-succeeded response was CR in 9.1% of cases, PR in 19.1%, SD in 10.9%, and PD in 60.9% of cases; overall, 43 (39.1%) patients obtained DC.

After a median follow-up of 22.9 mo (95%CI: 17.3-38.1), the cumulative median survival of the overall population was 13.4 mo (95%CI: 10.6-17.0, Figure 1). A total of 66 patients died and the most prevailing cause of death was attributed to tumor progression (50/66; 75.7%), followed by liver function failure (13/66; 19.7%), while in the remaining 3 patients, the death was caused by sepsis, post LT complications and bone fracture.

At univariate analysis, AFP serum level > 200 ng/mL, tumor size > 5 cm, the presence of macrovascular invasion, the presence of macrovascular invasion and/or extrahepatic spread as pre-treatment factors and the absence of DC as post-treatment factor were considered to be correlated with a worse outcome (Table 2). However, at the multivariate Cox regression, only AFP serum level > 200 ng/mL and DC were independent predictors of mortality (HR = 2.194, 95%CI: 1.249-3.855, $P = 0.006$ and HR = 0.190, 95%CI: 0.098-0.367, $P < 0.0001$, respectively). In particular, the effect of these two variables was reverse in a time dependent


Table 2 Univariate (Kaplan-Meier) and multivariate (Cox proportional hazard regression) survival analysis of patients with Barcelona Clinic Liver Cancer C hepatocellular carcinoma according to clinical and tumor variables

Variable	Univariate analysis		Multivariate analysis	
	Survival time (mo)	P value	Hazard ratio (95%CI)	P value
Age				
< 65 yr	13.9	0.903	-	-
≥ 65 yr	13.8			
Gender				
Male	13	0.900	-	-
Female	14.2			
PS				
0	10.3	0.128	-	-
1/2	13.9			
Diabetes				
No	13	0.813	-	-
Yes	13.8			
Child-Pugh score				
A	13.4	0.957	-	-
B	12.8			
N nodules				
Single	13.8	0.776	-	-
2-3	13.4			
Multinodular/infiltrating	13			
Tumor size				
≤ 5 cm	13.9	0.022 ¹	1	0.275
> 5 cm	9.9		1.357 (0.784-2.349)	
Macrovascular invasion				
No	15.8	0.014 ¹	1	0.866
Yes	9.5		1.095 (0.379-3.162)	
Extrahepatic spread				
No	11.2	0.274	-	-
Yes	6.7			
Macrovascular invasion and/or extrahepatic spread				
No	13.8	0.008 ¹	1	0.429
Yes	6.3		1.547 (0.523-4.571)	
AFP				
≤ 200 ng/mL	15.8	0.0002 ¹	1	0.006 ¹
> 200 ng/mL	6.3		2.194 (1.249-3.855)	
DC				
No	7.6	< 0.0001 ¹	1	< 0.0001 ¹
Yes	15.8		0.190 (0.098-0.367)	
NIACE score				
≤ 3	13.8	0.515	-	-
> 3	6.7			

¹Statistically significant results. PS: Performance status; AFP: Alpha-fetoprotein; DC: Disease control.

manner, as depicted by plotting the log hazard ratios (beta) over time (Figure 2). In the first 6 mo of follow-up, serum AFP > 200 ng/mL was directly associated with lower chances of survival, but the effect declined subsequently. Conversely, the favorable prognostic impact of DC curtailed in the early-intermediate period and became noticeable after 1 year of follow-up.

A term of interaction of these two covariates with time was then introduced in the Cox model and hazard

**Figure 1** Cumulative survival of the overall cirrhotic patients with Barcelona Clinic Liver Cancer C stage hepatocellular carcinoma included in the study. The solid line shows the overall survival and the dotted lines the 95% CIs.

ratios were reported by each time interval (≤ 6 mo, 7-12 mo, > 12 mo; Table 3). The AFP serum level > 200 ng/mL was significantly associated with higher risk of mortality within the first 6 mo of patients' entry into the BCLC stage C (≤ 6 mo, HR = 5.073, 95%CI: 2.159-11.916, $P = 0.0002$). Conversely, DC exercised a significant protective effect in long-term phase (> 12 mo, HR = 0.110, 95%CI: 0.038-0.314, $P < 0.0001$).

There were also identified 5 patients who had unexpectedly longer survival (above the 95th percentile; median 63.3 mo). The characteristics of those subjects have been described in Table 4; outstandingly, in most of the cases (3/5) PS 1-2 was the major cause for categorizing them in BCLC stage C. Pre-treatment AFP serum level was ≤ 200 ng/mL in all these patients; and two of them showed tumor macrovascular invasion without any extrahepatic spread. In one case Sorafenib, and in another TARE was prescribed; whereas, in the remaining three patients, curative treatments (LT), DSM-TACE or second-line systemic therapies were administered. Remarkably, DC was achieved in all these long-term survivors.

Secondary endpoint: DC

The examination of factors associated with DC was the second landmark of the study (Table 5). The patients who achieved DC (43/110; 39.1%) were illustrated by small-size tumors (> 5 cm: 13/43, 30.2% vs 41/67, 61.2%; $P = 0.002$), a lower frequency of macrovascular invasion (11/43, 25.6% vs 39/67, 58.2%; $P = 0.0009$), extrahepatic spread (3/43, 7% vs 16/67, 23.9%; $P = 0.036$) and of macrovascular invasion and/or extrahepatic spread (14/43, 32.6% vs 47/67, 70.1%; $P = 0.0001$), lower AFP serum level (> 200 ng/mL: 8/43, 18.6% vs 28/67, 41.8%; $P = 0.013$) and more frequently received at least one treatment (39/43, 90.7% vs 49/67, 73.1%; $P = 0.029$). However, only the presence of macrovascular

Table 3 Multivariate Cox regression model including alpha-fetoprotein and disease control as time dependent covariates

Variable	Multivariate analysis	
	Hazard ratio (95%CI)	P value
Macrovascular invasion		
No	1	0.917
Yes	1.066 (0.412-2.762)	
Macrovascular invasion and/or extrahepatic spread		
No	1	0.366
Yes	1.552 (0.584-4.124)	
Tumor size		
≤ 5 cm	1	0.266
> 5 cm	1.369 (0.786-2.382)	
AFP (> 200 ng/mL vs ≤ 200 ng/mL)		
< 6 mo	5.073 (2.159-11.916)	0.0002 ¹
7-12 mo	0.948 (0.275-3.267)	0.932
> 12 mo	1.698 (0.620-4.648)	0.303
DC (Yes vs No)		
< 6 mo	0.220 (0.075-0.650)	0.096
7-12 mo	0.463 (0.181-1.189)	0.109
> 12 mo	0.110 (0.038-0.314)	< 0.0001 ¹

For all other variables single hazard ratios were reported. ¹Statistically significant results. AFP: Alpha-fetoprotein; DC: Disease control.

invasion and/or extrahepatic spread was independently associated with reduced likelihoods of achieving DC (OR 0.263, 95%CI: 0.111-0.622, $P = 0.002$). It is important to mention that among the 61 patients who showed macrovascular invasion and/or metastases, 44 (72.1%) received treatment and this proportion was significantly lower than that of patients showing intrahepatic disease without vascular involvement (44/49, 89.8%, $P = 0.029$).

DISCUSSION

The BCLC staging system is the most widely used approach for the therapeutic and prognostic classification of cirrhotic patients with HCC. While exploring the implementation of biomarker research in clinical practice to stratify tumors based on their biological aggressiveness^[11], several sub-classifications of the BCLC stages consistent with prognostic factors and new scores have been proposed to improve the predictive power of this algorithm^[12-14]. A more detailed stratification system based on the life expectancy may avoid offering treatments having a poor impact on patients' prognosis and often impairing the quality of life. These considerations are extremely important with regard to the selection of patients for the clinical trials of first or second line novel systemic agents.

The present study was aimed at investigating the predictors of survival in cirrhotic patients with BCLC stage C HCC and at assessing their effect in a time dependent manner. At the preliminary survival analysis, AFP serum level > 200 ng/mL and DC were found to be independent predictors of mortality (HR = 2.194, $P = 0.006$ and HR = 0.190, $P < 0.0001$, respectively).

Hence, the first finding of our report confirms




Figure 2 Plot of the scaled Schoenfeld residuals over time for alpha-fetoprotein serum level > 200 ng/mL (A) and disease control (B). The solid line shows the log of hazard ratio (beta) as a function of survival time with the 95%CI (dotted lines). The average beta value obtained at the Cox model without any time-adjustment is also reported (solid red line).

high AFP serum level as a negative predictive marker in patients with advanced HCC and its impact on survival irrespective of the tumor stage at the time of diagnosis^[15-20]. Furthermore, although this category of patients is classified as "advanced stage", we demonstrated a promising impact of the response to treatment, as shown by DC, on prognosis. Based on these findings, curative and locoregional treatments should not be "a priori" excluded in a subset of BCLC stage C patients with favorable predictive factors. As reported previously, surgical resection and LT can extend patients' survival in the BCLC stage C also^[4-6,8,9,21], which supports the need of a novel method of prediction more customized to the specific patient. The identification of 5 long-term survivors (median 63.3 mo), where 3 were included in this stage only at impaired PS (1 or 2) in absence of vascular invasion or extrahepatic tumor spread, confirms the heterogeneity of patients included in the BCLC stage C and the benefits they got in terms of DC. In four patients, locoregional treatments were feasible and two of them were subjected to LT successfully. As already reported^[22], the provision based on PS used in the BCLC algorithm is questionable. Furthermore, PS scores are subjective measures with high inter-observer variability, and it is often difficult to correctly evaluate tumor-related symptoms in patients already presenting compromised general conditions. In the current study, PS has not been found to be an independent predictor of survival, and this supports the hypothesis that alone it cannot be considered as an

Table 4 Characteristics of the 5 patients with long-survival (median 63.3 mo)

PT	Gender	Age	Etiology	PS	Child-Pugh	AFP > 200 ng/mL	No. of nodules	Maximum size	Macrovascular invasion	Extrahepatic spread	Diabetes	Pre-BCLC C treatments	Post-BCLC C treatments	Best response	DC	Survival (mo)	Status
PT3	M	65	HBV	1	A	No	Infiltrating	Infiltrating	Yes	No	No	None	Sorafenib	CR	Yes	79.4	Alive
PT10	M	73	HCV	1	A	No	> 3	18	No	No	No	TACE, resection, sorafenib	Second line systemic agent, DSM-TACE (2)	SD	Yes	63.3	Alive
PT27	M	58	HBV	2	B	No	2	19	No	No	No	RFA, TACE	LT	CR	Yes	67.1	Alive
PT53	M	63	Alcohol	1	B	No	> 3	50	No	No	No	None	TACE (4), TACE + RFA (1), LT	CR	Yes	58.9	Alive
PT54	M	65	HCV	0	A	No	Single	40	Yes	No	Yes	None	TARE (2)	SD	Yes	38.1	Alive

HBV: Hepatitis B virus; HCV: Hepatitis C virus; PS: Performance status; BCLC: Barcelona Clinic Liver Cancer; AFP: Alphafetoprotein; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; DSM-TACE: Degradable starch microspheres transarterial chemoembolization; LT: Liver transplant; TARE: Transarterial radioembolization; CR: Complete response; SD: Stable disease; DC: Disease control.

exclusion criterion for curative treatments. Outstandingly, the majority of the patients (88.2%) in our series showed a PS 0 or 1, and therefore, only a small subgroup of patients (11.7%) fell in PS 2 class, and that may have influenced the overall survival insignificantly. However, the non-homogeneity of PS stages among BCLC C patients may be attributed to the sequential enrollment of the subjects included in the analysis rather than a selection-bias, and gives a better understanding of what happens in the real field practice.

The novel finding surfaced out from our study is the dynamic influence of AFP serum level and DC on survival period (Figure 2). In particular, the log curve of the hazard ratio for AFP serum level > 200 ng/mL elevated at high beta points implying a direct correlation with mortality, but declined steadily over time. This was more evident during the early follow-up (within 6 mo), which reached the zero point and then increased slightly afterwards, and finally became constant in the later stage. The DC beta value showed an inverse tendency, being constantly negative and increasing towards the zero point at about 6 mo of follow-up; however, it decreased significantly after the first year. At the Cox regression model including time-dependent coefficients, the most noticeable prognostic effect of AFP appeared in the early follow-up period, with 83.5% probability of mortality during the first 6 mo of follow-up of patients with AFP serum level > 200 ng/mL compared to those with a lower value (HR 5.073, 95%CI: 2.159-11.916, $P = 0.0002$). On the other hand, the DC was found to be defensive against death, as evident especially in the long-term follow-up (> 12 mo, HR 0.110, $P < 0.0001$). This type of dynamic behavior of prognostic factors has not been documented earlier during the establishment of HCC, while for other malignancies, such as breast, lung, and colorectal cancer, it has already been described. Time-dependent analysis has allowed to model patients' survival more precisely, considering the dynamic behavior of mortality risk factors and pointing out the reverse effect of AFP serum level and DC on prognosis temporally. Our findings, therefore, emphasize that tumor biological aggressiveness remains the most important short time prognostic indicator whereas in the long term, the achievement of DC is very decisive to ameliorate patients' survival expectancy. This further supports the efforts towards improving the therapy management and also implementing the treatment options in the BCLC algorithm for stage C patients. Nevertheless, since high AFP serum level is associated with an increased risk of early mortality, the trials assaying new systemic agents or second line therapies should be very careful in selecting the patients, and consequences should be evaluated optimally based on the stratification of the biological aggressiveness.

The second milestone of our study was to identify predictive factors of DC. The presence of macrovascular invasion and/or extrahepatic spread was found to be independently associated with a reduced likelihood of achieving DC (OR = 0.263, $P = 0.002$). The negative effect of tumor diffusion outside the liver or into the bloodstream on patients' prognosis is well known, as thoroughly discussed in previous reports^[23-25], and this could be indirectly due to the inadequacy of the currently available treatments to control an aggressive disease in an effective and systemic manner. Nevertheless, in our study the 61 patients showing macrovascular invasion and/or extrahepatic spread received treatment with a lower frequency as compared to those with non-invasive tumors (44/61, 72.1% vs 44/49, 89.8%, $P = 0.029$). Due to the extensive tumor burden, in this subgroup of patients supportive care was taken more often and this may also be the reason for the reduced DC rates to some extent.

Table 5 Univariate (Fisher's exact test) and multivariate (binomial logistic regression) analysis of factors associated with the achievement of disease control in patients with Barcelona Clinic Liver Cancer C hepatocellular carcinoma

Variable	DC (43)	No DC (67)	Univariate analysis	Multivariate analysis	
			P value	Odds ratio (95%CI)	P value
Age					
< 65 yr	15	27	0.229	-	
≥ 65 yr	28	40			
Gender					
Male	35	56	0.471	-	
Female	8	11			
PS					
0	37	60	0.06	-	
1/2	6	7			
Diabetes					
No	34	53	0.653	-	
Yes	9	14			
Child-Pugh score					
A	31	51	0.524	-	
B	12	16			
N nodules					
Single	13	22	0.078	-	
2-3	11	9			
Multinodular/infiltrating	19	36			
Tumor size					
≤ 5 cm	30	26	0.006 ¹	1 0.617 (0.236-1.610)	0.298
> 5 cm	13	41			
Macrovascular invasion					
No	32	28	0.0003 ¹	-	-
Yes	11	39			
Extrahepatic spread					
No	40	51	0.02 ¹	-	-
Yes	3	16			
Macrovascular invasion and/or extrahepatic spread					
No	29	20	< 0.0001 ¹	1 0.263 (0.111-0.622)	0.002 ¹
Yes	14	47			
AFP					
≤ 200 ng/mL	35	39	0.008 ¹	1 0.461 (0.169-1.258)	0.179
> 200 ng/mL	8	28			
NIACE score					
≤ 3	34	50	0.502	-	
> 3	9	17			
Treatment after BCLC C diagnosis					
No	4	18	0.04 ¹	1 0.531 (0.147-1.917)	0.270
Yes	39	49			

¹Statistically significant results. PS: Performance status; AFP: Alpha-fetoprotein; DC: Disease control.

Recently, the NIACE score has been proposed as a useful tool for the prognostic sub-staging of BCLC stage C patients, as well as for the management of treatment and for the selection of patients in clinical trials^[14]. Probably, the different biological characters of tumors encompassed in our investigation could have negatively affected the prognostic ability of the NIACE score. Indeed, only 14% of the patients in the NIACE study cohort had previously undergone a treatment for HCC, as compared to 51.8% of the patients in our series, and the prevalence of alcohol related liver disease was higher than in our series of patients (30% vs 15.5%).

A possible limitation of this study could be its retrospective nature, although this was partially overcome by the rigorous and prospective collection of clinical records by the multidisciplinary group. Despite

of having limited the number of records included in the analysis, the inclusion of patients treated only at our Center has reduced biasness related to diverse modalities of treatment or imaging interpretation by radiologists at different Centers.

The liver function did not appear to have a significant impact on patients' prognosis in our analysis; probably, a high tumor-related mortality has overcome the impact of hepatic impairment on survival. However, this cannot be absolutely confirmed, as the number of patients with conserved liver function largely exceeded that of patients with more severe liver impairment (74.5% Child A vs 25.5% Child B class).

In conclusion, our data confirm that the BCLC stage C comprises a huge heterogeneous group of cirrhotic patients suitable for locoregional and potentially curative treatments. This is the first report highlighting the reverse

and time-dependent effect of AFP serum level and DC as prognostic factors in cirrhotic patients with advanced stage HCC. In the patients with pre-treatment AFP serum level > 200 ng/mL the risk of early death increases up to 80%, while the achievement of post-treatment DC, which is less likely in the presence of macrovascular invasion and/or extrahepatic tumor spread, suggests higher chances of long-term survival. The combination of these predictive factors may be helpful in the sophistication of patients' prognosis, thereby being valuable in the selection of patients suitable for clinical trials and in designing the therapeutic strategy.

ARTICLE HIGHLIGHTS

Research background

Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) includes a heterogeneous group of patients with different clinical and tumor characteristics and survival expectancy, for whom sorafenib is the only recommended treatment option. The present study investigates the outcome of BCLC C patients who underwent different locoregional, surgical or systemic treatments.

Research motivation

To better stratify the prognosis of patients with BCLC C stage HCC.

Research objectives

To characterize the prognosis of cirrhotic patients with BCLC stage C HCC as assessed by a multidisciplinary team in an Italian tertiary care center and to identify those factors predicting the achievement of disease control (DC).

Research methods

The prospective database of the Hepatocatt multidisciplinary group, containing clinical, tumor and outcome data of all liver cancer subjects evaluated in the seven years at our Institute was reviewed.

Research results

The study confirms that the BCLC stage C comprises a huge heterogeneous group of cirrhotic patients suitable for locoregional and potentially curative treatments. Moreover, this is the first report highlighting the reverse and time-dependent effect of alphafetoprotein (AFP) serum level and DC as prognostic factors in cirrhotic patients with advanced stage HCC.

Research conclusions

The novel finding surfaced out from our study is the dynamic influence of AFP serum level and DC on survival period. In particular, the AFP serum level > 200 ng/mL was significantly associated with higher risk of mortality within the first 6 mo of patients' entry into the BCLC stage C; conversely, DC exercised a significant protective effect in long-term phase. Our report also highlight that the presence of macrovascular invasion and/or extrahepatic spread is independently associated with a reduced likelihood of achieving DC. Based on these findings, curative and locoregional treatments should not be "a priori" excluded in a subset of BCLC stage C patients. Indeed, predictive factors may be helpful in the sophistication of patients' prognosis, thereby being valuable in the selection of patients suitable for clinical trials and in designing the therapeutic strategy.

Research perspectives

Given the higher number of heterogeneous and complex cases encountered in the field-practice, the BCLC classification is often not exhaustive, and the increasing number of new therapeutic options and their combinations makes difficult to strictly adhere to BCLC suggestions. New algorithms for the stratification of patients' prognosis are needed to improve clinical practice.

REFERENCES

- 1 **European Association For The Study Of The Liver**; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
- 2 **Bruix J**, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
- 3 **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
- 4 **Hernández-Guerra M**, Hernández-Camba A, Turnes J, Ramos LM, Arranz L, Mera J, Crespo J, Quintero E. Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. *United European Gastroenterol J* 2015; **3**: 284-293 [PMID: 26279838 DOI: 10.1177/2050640615575971]
- 5 **Borzio M**, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, Francica G, Salvagnini M, Marignani M, Salmi A, Farinati F, Carella A, Pedicino C, Dionigi E, Fanigliulo L, Cazzaniga M, Ginanni B, Sacco R; EpaHCC Group. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. *Future Oncol* 2013; **9**: 283-294 [PMID: 23414477 DOI: 10.2217/fon.12.183]
- 6 **Leoni S**, Piscaglia F, Serio I, Terzi E, Pettinari I, Croci L, Marinelli S, Benevento F, Golfieri R, Bolondi L. Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. *Dig Liver Dis* 2014; **46**: 549-555 [PMID: 24630947 DOI: 10.1016/j.dld.2014.02.012]
- 7 **Mazzaferro V**, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, Maccauro M, Marchianò A, Bongini M, Lanocita R, Civelli E, Bombardieri E, Camerini T, Spreafico C. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. *Hepatology* 2013; **57**: 1826-1837 [PMID: 22911442 DOI: 10.1002/hep.26014]
- 8 **Torzilli G**, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. *Ann Surg* 2013; **257**: 929-937 [PMID: 23426336 DOI: 10.1097/SLA.0b013e31828329b8]
- 9 **Vitale A**, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U; Italian Liver Cancer (ITA. LI.CA) group. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study. *J Hepatol* 2015; **62**: 617-624 [PMID: 25450706 DOI: 10.1016/j.jhep.2014.10.037]
- 10 **Lencioni R**, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 2010; **30**: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]
- 11 **Zucman-Rossi J**, Villanueva A, Nault JC, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. *Gastroenterology* 2015; **149**: 1226-1239.e4 [PMID: 26099527 DOI: 10.1053/j.gastro.2015.05.061]
- 12 **Bolondi L**, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal

- for a subclassification to facilitate treatment decisions. *Semin Liver Dis* 2012; **32**: 348-359 [PMID: 23397536 DOI: 10.1055/s-0032-1329906]
- 13 **Farinati F**, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacomini A, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U; ITA.LI.CA study group. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. *PLoS Med* 2016; **13**: e1002006 [PMID: 27116206 DOI: 10.1371/journal.pmed.1002006]
 - 14 **Adhoute X**, Pénaranda G, Raoul JL, Blanc JF, Edeline J, Conroy G, Perrier H, Pol B, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Bronowicki JP, Bourlière M. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study. *Eur J Gastroenterol Hepatol* 2016; **28**: 433-440 [PMID: 26695429 DOI: 10.1097/MEG.0000000000000558]
 - 15 **Pompili M**, Rapaccini GL, Covino M, Pignataro G, Caturelli E, Siena DA, Villani MR, Cedrone A, Gasbarrini G. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. *Cancer* 2001; **92**: 126-135 [PMID: 11443618]
 - 16 **Farinati F**, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? *Am J Gastroenterol* 2006; **101**: 524-532 [PMID: 16542289 DOI: 10.1111/j.1572-0241.2006.00443.x]
 - 17 **Khalaf N**, Ying J, Mittal S, Temple S, Kanwal F, Davila J, El-Serag HB. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. *Clin Gastroenterol Hepatol* 2017; **15**: 273-281.e1 [PMID: 27521507 DOI: 10.1016/j.cgh.2016.07.033]
 - 18 **Kudo M**, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M; Liver Cancer Study Group of Japan. Survival Analysis over 28 Years of 173378 Patients with Hepatocellular Carcinoma in Japan. *Liver Cancer* 2016; **5**: 190-197 [PMID: 27493894 DOI: 10.1159/000367775]
 - 19 **Duvoux C**, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α -fetoprotein improves the performance of Milan criteria. *Gastroenterology* 2012; **143**: 986-994.e3; quiz e14-15 [PMID: 22750200 DOI: 10.1053/j.gastro.2012.05.052]
 - 20 **Hameed B**, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. *Liver Transpl* 2014; **20**: 945-951 [PMID: 24797281 DOI: 10.1002/lt.23904]
 - 21 **Vitale A**, Morales RR, Zanusi G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; Italian Liver Cancer group. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. *Lancet Oncol* 2011; **12**: 654-662 [PMID: 21684210 DOI: 10.1016/S1470-2045(11)70144-9]
 - 22 **Hsu CY**, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Lee RC, Chiou YY, Lee FY, Huo TI. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. *Hepatology* 2013; **57**: 112-119 [PMID: 22806819 DOI: 10.1002/hep.25950]
 - 23 A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. *Hepatology* 1998; **28**: 751-755 [PMID: 9731568 DOI: 10.1002/hep.510280322]
 - 24 **Liu PH**, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, Lee FY, Lin HC, Huo TI. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. *J Hepatol* 2016; **64**: 601-608 [PMID: 26551516 DOI: 10.1016/j.jhep.2015.10.029]
 - 25 **Ponziani FR**, Bhoori S, Germini A, Bongini M, Flores M, Sposito C, Facciorusso A, Gasbarrini A, Mazzaferro V. Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. *Liver Int* 2016; **36**: 1033-1042 [PMID: 26709844 DOI: 10.1111/liv.13052]

P- Reviewer: Makisalo H, Zhao HT **S- Editor:** Ji FF
L- Editor: A **E- Editor:** Li D





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

